ORIGINAL RESEARCH
Published on 09 Jan 2025
Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study
doi 10.3389/fimmu.2024.1483956
- 908 views